Global Generic Pharmaceuticals Market

Global Generic Pharmaceuticals Market

  • May 2016 •
  • 137 pages •
  • Report ID: 3837529 •
  • Format: PDF
Market Participants Aim at High Valued-added Segments, with a Big Emphasis on Branded Generics and Biosimilars

The key objectives of this research service are to gain an in-depth knowledge of the major markets and therapeutic areas and organizations presenting significant growth opportunities for generics, to understand the impact of regulation on the market, and to outline the industry consolidation trends that will continue shaping the future of generics. It would enable market participants to take strategic decisions to stay ahead of their competitors and gain a significant share in the market. Additional highlights of the report include top attractive segments, revenue forecasts, key trends and market opportunities, companies to watch, and different market models.

Key findings
Current Market Dynamics
- Increased revenue from both established and developing markets: In 2015, generic drugs were valued at $ Billion, with a % share of the global pharmaceutical market.
By the end of 2020, revenue from generics is expected to reach $ Billion, at an annual growth rate of %, while the global pharmaceutical market is growing at CAGR (2015–2020) of %.
- US still the big opportunity: % of prescriptions are generics. Growing at a CAGR (2015–2020) of %, with a share of % of the entire pharmaceutical market, they were valued at $ Billion in 2015.
- Emerging markets the next big fish: India, China, Brazil, and Russia seem lucrative in terms of growth and opportunity due to their bigger market share and growth rate compared to other developing countries.
o China ranks second, with % share of the global generics market, valued at $ Billion and growing at a CAGR (2015–2020) of %.
o India has emerged as a major market for consumption as well as manufacturing of generics, targeting exports of more than % to the US each year.
- Increased acceptance of biosimilars: EU countries are leading the way. US is still in nascent stage.
- Demographic and economic changes: Rising cost due to an ageing population, increased life expectancy, and higher incidence of chronic diseases are contributing to the increased use and acceptance of generics.
- Leveraging Mergers and Acquisitions (M&A) for economies of scale and technology transfer: An average of deals (consolidation, divestiture, and spin-off) are transacted every quarter.

Total Generic Pharmaceuticals Market: Key Trends, Global, 2015
Patent expiration and increased usage of traditional generic drugs are curbing the cost, as a result, focus of the industry is shifting towards investment in specialty drugs.
- With innovation and technology, generics can be enhanced to deliver additional benefits.
For instance, SUBACAP is an improved version of itraconazole (used for fungal infection treatment). Price could vary from moderate to high.
- Creating a premium pricing portfolio by using innovative platforms can give a great mileage to generics companies to charge a premium price. The launch of Mylan's
Women's Care portfolio in India is a step in that direction.
- Furthermore, to beat the competition, several generics companies are transforming themselves from low-margin formulation to high-margin formulation manufacturers.
- Biosimilars is a massive opportunity. Regardless of a slow start, it will eventually be a huge business. As per Frost & Sullivan’s estimate, $70–$80 Billion worth of biologic drugs will lose exclusivity in the next five years.
- The launch of innovative production platforms will reduce the cost of biosimilar production, thus, providing substantial price differentiation.
- Creating a premium pricing portfolio by using innovative platforms can give a great mileage to generics companies to charge a premium price. The launch of Mylan's
Women's Care portfolio in India is a step in that direction.
- Furthermore, to beat the competition, several generics companies are transforming themselves from low-margin formulation to high-margin form